Saab 9-5 to the base models and the Aero. Six-speed manual transmission was not offered in first-generation 9-5s. In 2005, an updated version of the 2.0 L turbocharged I4 was introduced in the European market together with the 2006 9-5. The engine was sold as "2.0T BioPower", optimized to run on E85 producing 132 kW (180 hp) at 5500 rpm. There was also a 2.3T BioPower version sold from 2007. It was also introduced in Australia. There is a Saab 9-5 E100 Concept, based on the turbo 2.0. The 9-5 introduced Saab's Active Head Restraints (SAHR), which moved up and forward to
7+3 (chemotherapy) doxorubicin or idarubicin or mitoxantrone). There were attempts to intensify the "7+3" regimen in order to try to improve its efficacy. Attempts were made to prolong the course (cytarabine for 10 days instead of 7, or daunorubicin/idarubicin for 4–5 days instead of 3). On the other hand, there were attempts to minimize the toxicity of the regimen by reducing the dose or the duration of the course. But this proved to compromise the efficacy of the regimen. The addition of vinca alkaloids (vincristine or vinblastine) to the "7+3" regimen, which addition was quite popular in AML in old times (when